Millennium Management LLC Has $5.78 Million Stock Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Millennium Management LLC trimmed its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 34.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,894,126 shares of the biopharmaceutical company's stock after selling 986,762 shares during the period. Millennium Management LLC owned 3.86% of Puma Biotechnology worth $5,777,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Graham Capital Management L.P. bought a new position in shares of Puma Biotechnology in the 4th quarter valued at $33,000. D. E. Shaw & Co. Inc. raised its position in Puma Biotechnology by 287.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 222,608 shares of the biopharmaceutical company's stock worth $679,000 after purchasing an additional 165,220 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Puma Biotechnology during the 4th quarter worth $99,000. Bank of America Corp DE raised its position in Puma Biotechnology by 103.1% during the 4th quarter. Bank of America Corp DE now owns 82,339 shares of the biopharmaceutical company's stock worth $251,000 after purchasing an additional 41,790 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new position in Puma Biotechnology during the 4th quarter worth $54,000. 61.29% of the stock is currently owned by institutional investors.

Puma Biotechnology Trading Down 1.5%

NASDAQ:PBYI traded down $0.05 during trading hours on Friday, hitting $3.33. 251,209 shares of the company were exchanged, compared to its average volume of 436,842. The stock has a market capitalization of $165.27 million, a price-to-earnings ratio of 6.94 and a beta of 1.29. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a one year low of $2.23 and a one year high of $4.13. The company has a fifty day simple moving average of $3.07 and a 200 day simple moving average of $3.08.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $59.10 million during the quarter, compared to analyst estimates of $52.50 million. Sell-side analysts expect that Puma Biotechnology, Inc. will post 0.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PBYI has been the subject of several analyst reports. Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.